Table 2.

Prevalence of selected non-actionable mutations in the overall study population and by treatment group

Mutation	All treatments combined			Chemotherapy			ICI-containing
	OR [95% CI]	p value	mutated/wild-type	OR [95% CI]	p value	mutated/wild-type	OR [95% CI]	p value	mutated/wild-type
STK11
Non-FP	1.68 [1.41–2.01]	< 0.001	294/1385	1.84 [1.36–2.48]	0.06	109/519	1.62 [1.30–2.01]	< 0.001	185/866
FP			338/945			112/290			226/655
Non-LTS	0.37 [0.27–0.50]	< 0.001	586/1919	0.42 [0.24–0.73]	0.002	206/689	0.34 [0.23–0.51]	< 0.001	380/1230
LTS			46/411			15/120			31/291
Male	1.06 [0.89–1.27]	0.48	333/1267	1.43 [10.6–1.93	0.02	103/456	0.91 [0.73–1.13]	0.40	230/811
Female			306/1093			118/365			188/728
Non-smoker	2.30 [1.36–3.91]	0.001	16/132	1.69 [0.75–3.81]	0.20	7/43	2.80 [1.40–5.86]	0.004	9/89
Smoker			623/2228			214/778			409/1450
KEAP1
Non-FP	1.60 [1.29–1.99]	< 0.001	180/1499	1.59 [1.10–2.29]	0.0136	67/561	1.61 [1.23–2.10]	< 0.001	113/938
FP			207/1076			64/338			143/738
Non-LTS	0.61 [0.44–0.86]	0.004	346/2159	0.64 [0.34–1.19]	0.15	119/776	0.60 [0.40–0.91]	0.015	227/1383
LTS			41/416			12/123			29/293
Male	0.85 [0.69–1.06]	0.15	222/1378	1.05 [0.72–1.51]	0.81	69/490	0.77 [0.58–1.00]	0.05	153/888
Female			169/1230			62/421			107/809
Non-smoker	4.48 [1.82–11.00]	< 0.001	5/143	2.32 [0.71–7.57]	0.15	3/47	7.74 [1.90–31.57]	0.004	2/96
Smoker			386/2465			128/864			258/1601
CDKN2A/B
Non-FP	1.28 [1.09–1.50]	0.002	482/1197	1.74 [1.34–2.28]	0.04	170/458	1.09 [0.90–1.33]	0.37	312/739
FP			436/847			158/244			278/603
Non-LTS	0.71 [0.57–0.89]	0.003	803/1702	0.60 [0.39–0.92]	0.02	297/598	0.77 [0.59–1.01]	0.06	506/1104
LTS			115/342			31/104			84/238
Male		0.05	525/1075	0.75 [0.58–0.98]	0.04	195/364	0.92 [0.76–1.11]	0.39	330/711
Female			413/986			139/344			274/642
Non-smoker		0.22	53/95	0.83 [0.46–1.50]	0.54	18/32	0.79 [0.52–1.21]	0.29	35/63
Smoker	0.81 [0.57–1.14]		885/1966			316/676			560/1290
KRAS
Non-FP	1.05 [0.90–1.21]	0.53	694/985	1.10 [0.85–1.43]	0.46	214/414	0.98 [0.82–1.18]	0.87	480/571
FP			545/738			146/256			399/482
Non-LTS	1.43 [1.17–1.74]	< 0.001	1014/1491	1.15 [0.79–1.67]	0.46	309/586	1.51 [1.19–1.92]	< 0.001	705/905
LTS			225/232			51/84			174/148
Male	1.98 [1.71–2.30]	< 0.001	547/1053	1.82 [1.41–2.36]	0.004	160/399	2.09 [1.74–2.50]	< 0.001	387/654
Female			710/689			204/279			506/410
Non-smoker	1.20 [0.85–1.68]	0.30	56/92	1.27 [0.68–2.35]	0.45	15/35	1.18 [0.78–1.78]	0.44	41/57
Smoker			1201/1650			349/643			852/1007
FGFR1/2/3
Non-FP	1.17 [0.87–1.58]	0.29	98/1581	1.01 [0.64–1.60]	0.96	51/577	1.39 [0.93–2.08]	0.10	47/1004
FP			87/1196			33/369			54/827
Non-LTS	0.57 [0.35–0.94]	0.03	167/2338	0.49 [0.21–1.14]	0.09	78/817	0.66 [0.36–1.22]	0.19	89/1521
LTS			18/439			6/129			12/310
Male	0.58 [0.43–0.79]	< 0.001	122/1478	0.49 [0.30–0.79]	0.003	58/501	0.66 [0.44–1.00]	0.05	64/977
Female			64/1335			26/457			38/878
Non-smoker	2.45 [0.90–6.71]	0.07	4/144	4.47 [0.61–32.82]	0.11	1/49	1.78 [0.55–5.72]	0.33	3/95
Smoker			182/2669			83/909			99/1760
APC
Non-FP	1.11 [0.73–1.67]	0.63	51/1628	1.11 [0.59–2.10]	0.74	24/604	1.15 [0.67–1.99]	0.61	27/1024
FP			43/1240			17/385			26/855
Non-LTS	0.88 [0.48–1.59]	0.66	81/2424	0.51 [0.16–1.68]	0.26	38/857	1.17 [0.58–2.35]	0.66	43/1567
LTS			13/444			3/132			10/312
Male	0.53 [0.34–0.82]	0.003	64/1536	0.36 [0.17–0.74]	0.004	31/528	0.68 [0.39–1.20]	0.18	33/1008
Female			30/1369			10/473			20/896
Non-smoker	4.96 [0.69–35.81]	0.08	1/147	–	0.14	0/50	2.79 [0.38–20.41]	0.31	1/97
Smoker			93/2758			41/951			52/1807

CI confidence interval, ICI immune checkpoint inhibitors, FP fast progressors, LTS long-term survivors, OR odds ratio